2335 GMT - Alcidion's bull at Bell Potter expects a big jump in the medical-tech provider's cash balance over its 2H FY. Analyst Thomas Wakim tells clients in a note that the Australian company's 2Q update shows contracted revenue for the current FY 2026 is already 6% higher than that across the whole of the previous FY. Although recorded a net operating cash outflow of A$1.9 million in the December quarter, Wakim points out that Alcidion's cash flow is typically lumpy and that it collected A$8.8 million in receipts across the first two weeks of January. This gives him confidence that it will end the FY significantly up on its current A$14.2 million balance. Bell Potter lifts its target price 13% to A$0.17 and maintains its buy rating. Shares are flat at A$0.135. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

January 15, 2026 18:35 ET (23:35 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.